Notice of Proposed Settlement of Stockholder Litigation. Click here for information.
Financials & Filings
OTCQB: INTI
PRICE:
This section of the Inhibitor Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Inhibitor Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
| Beta | -- |
|---|---|
| Shares Outstanding | -- |
| Average Volume (10 days) | -- |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | N/A |
|---|
| Strong Buy | 0 | |
|---|---|---|
| Buy | 0 | |
| Hold | 0 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
Paul D'Sylva Director | (19,100) Sell Jan 19, 2010 |
|---|---|
Paul D'Sylva Director | 12,000 Buy May 29, 2009 |
Paul D'Sylva Director | 510 Buy May 15, 2009 |
Paul D'Sylva Director | 2,800 Buy May 14, 2009 |
Paul D'Sylva Director | 23,934 Buy May 5, 2009 |
Get Important News and Updates by Email